303 related articles for article (PubMed ID: 28893104)
21. Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
Bonardi A; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):753-759. PubMed ID: 31438732
[No Abstract] [Full Text] [Related]
22. Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.
Tanihara H; Kakuda T; Sano T; Kanno T; Imada R; Shingaki W; Gunji R
Adv Ther; 2019 Feb; 36(2):333-343. PubMed ID: 30610614
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.
Tanihara H; Kakuda T; Sano T; Kanno T; Kurihara Y
Adv Ther; 2022 Apr; 39(4):1659-1677. PubMed ID: 35150417
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study.
Tanihara H; Kakuda T; Sano T; Kanno T; Gunji R
BMC Ophthalmol; 2020 Jul; 20(1):275. PubMed ID: 32646383
[TBL] [Abstract][Full Text] [Related]
25. The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15.
Sakata R; Fujishiro T; Saito H; Honjo M; Shirato S; Aihara M
Adv Ther; 2021 Jul; 38(7):3760-3770. PubMed ID: 34028695
[TBL] [Abstract][Full Text] [Related]
26. Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.
Lu LJ; Tsai JC; Liu J
Yale J Biol Med; 2017 Mar; 90(1):111-118. PubMed ID: 28356898
[TBL] [Abstract][Full Text] [Related]
27. Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection.
Kusuhara S; Nakamura M
Clin Ophthalmol; 2020; 14():1229-1236. PubMed ID: 32440089
[TBL] [Abstract][Full Text] [Related]
28. Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.
Schehlein EM; Robin AL
Drugs; 2019 Jul; 79(10):1031-1036. PubMed ID: 31134520
[TBL] [Abstract][Full Text] [Related]
29. Effect of ripasudil on diabetic macular edema.
Minami Y; Song YS; Ishibazawa A; Omae T; Ro-Mase T; Ishiko S; Yoshida A
Sci Rep; 2019 Mar; 9(1):3703. PubMed ID: 30842496
[TBL] [Abstract][Full Text] [Related]
30. Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.
Tanna AP; Johnson M
Ophthalmology; 2018 Nov; 125(11):1741-1756. PubMed ID: 30007591
[TBL] [Abstract][Full Text] [Related]
31. Ocular hypotensive efficacy of Src-family tyrosine kinase inhibitors via different cellular actions from Rock inhibitors.
Kirihara T; Shimazaki A; Nakamura M; Miyawaki N
Exp Eye Res; 2014 Feb; 119():97-105. PubMed ID: 24321889
[TBL] [Abstract][Full Text] [Related]
32. Rho/Rho-associated kinase pathway in glaucoma (Review).
Wang J; Liu X; Zhong Y
Int J Oncol; 2013 Nov; 43(5):1357-67. PubMed ID: 24042317
[TBL] [Abstract][Full Text] [Related]
33. Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys.
Kaneko Y; Ohta M; Isobe T; Nakamura Y; Mizuno K
J Ophthalmol; 2017; 2017():7079645. PubMed ID: 28540083
[TBL] [Abstract][Full Text] [Related]
34. Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy.
Goda E; Hirooka K; Mori K; Kiuchi Y
BMC Ophthalmol; 2019 Dec; 19(1):243. PubMed ID: 31791272
[TBL] [Abstract][Full Text] [Related]
35. A Rho-Associated Kinase Inhibitor Protects Permeability in a Cell Culture Model of Ocular Disease, and Reduces Aqueous Flare in Anterior Uveitis.
Yamada H; Yoneda M; Inaguma S; Gosho M; Murasawa Y; Isogai Z; Zako M
J Ocul Pharmacol Ther; 2017 Apr; 33(3):176-185. PubMed ID: 28157424
[TBL] [Abstract][Full Text] [Related]
36. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
[No Abstract] [Full Text] [Related]
37. Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine.
Chihara E; Dimitrova G; Chihara T
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1257-1264. PubMed ID: 29520478
[TBL] [Abstract][Full Text] [Related]
38. Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations.
Andrés-Guerrero V; García-Feijoo J; Konstas AG
Adv Ther; 2017 May; 34(5):1049-1069. PubMed ID: 28349508
[TBL] [Abstract][Full Text] [Related]
39. Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.
Terao E; Nakakura S; Fujisawa Y; Fujio Y; Matsuya K; Kobayashi Y; Tabuchi H; Yoneda T; Fukushima A; Kiuchi Y
Curr Eye Res; 2017 May; 42(5):738-742. PubMed ID: 27911106
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil.
Inoue K; Ishida K; Tomita G
Jpn J Ophthalmol; 2018 Jul; 62(4):508-516. PubMed ID: 29797109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
